# US 2013/0251784 A1 · Method for in vivo targeting of nanoparticles via bioorthogonal copper-free click chemistry

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251784 A1
- Document ID: US20130251784A1
- Status: Published application
- Kind: A1
- Application number: 13/774,247
- Filed: 2013-02-22
- Published: 2013-09-26
- Earliest claimed: 2012-03-20
- Assignees: Korea Institute of Science and Technology
- Applicants: Korea Institute of Science and Technology
- Inventors: Kwang Meyung KIM; Ick Chan KWON; Kuiwon CHOI; Heebeom KOO; Sang-min LEE; Inchan YOUN
- Web page: https://patentgrep.com/patent/US20130251784A1

## CPC

- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/555: {pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells}
- A61K 47/6911: {the form being a liposome}
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0052: {Small organic molecules (oligomers, polymers, dendrimers A61K49/0054)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to a method for in vivo targeting of a nanoparticle via bioorthogonal copper-free click chemistry, more particularly to a method for in vivo targeting of a nanoparticle, including: injecting a precursor capable of being metabolically engineered in vivo when injected into a living system and having a first bioorthogonal functional group into the living system; and injecting a nanoparticle having a second bioorthogonal functional group which can perform a bioorthogonal copper-free click reaction with the first bioorthogonal functional group attached thereto into the living system. In accordance with the present disclosure, accumulation of nanoparticles at a target site in a living system can be increased remarkably and the biodistribution of the nanoparticles can be controlled since the nanoparticles bound to a cell surface are taken up into the cell with time.

## Claims

### Claim 1

A method for in vivo targeting of a nanoparticle, comprising:
injecting a precursor capable of being metabolically engineered in vivo when injected into a living system and having a first bioorthogonal functional group into the living system; and
injecting a nanoparticle having a second bioorthogonal functional group which can perform a bioorthogonal copper-free click reaction with the first bioorthogonal functional group attached thereto into the living system.

### Claim 2 (depends on 1)

The method for in vivo targeting of a nanoparticle according to claim 1, wherein the metabolic engineering is metabolic glycoengineering.

### Claim 3 (depends on 1)

The method for in vivo targeting of a nanoparticle according to claim 1, wherein the precursor is a compound selected from a group consisting of Chemical Formulas 1 to 3:

### Claim 4 (depends on 1)

The method for in vivo targeting of a nanoparticle according to claim 1, wherein the first bioorthogonal functional group is an azide group.

### Claim 5 (depends on 1)

The method for in vivo targeting of a nanoparticle according to claim 1, wherein the second bioorthogonal functional group is a functional group capable of reacting with the first bioorthogonal functional group in vivo in the absence of a catalyst.

### Claim 6 (depends on 1)

The method for in vivo targeting of a nanoparticle according to claim 1, wherein the second bioorthogonal functional group is a compound selected from a group consisting of Chemical Formulas 4 to 15:

### Claim 7 (depends on 1)

The method for in vivo targeting of a nanoparticle according to claim 1, wherein the nanoparticle has a surface to which the second bioorthogonal functional group can be attached and has a size of 10-1000 nm such that in vivo circulation is possible.

### Claim 8 (depends on 1)

The method for in vivo targeting of a nanoparticle according to claim 1, wherein the nanoparticle is an organic nanoparticle, an inorganic nanoparticle or an organic-inorganic hybrid nanoparticle.

### Claim 9 (depends on 8)

The method for in vivo targeting of a nanoparticle according to claim 8, wherein the organic nanoparticle is selected from a group consisting of liposome, micelle, polymer carrier and protein nanoparticles and the inorganic nanoparticle is selected from a group consisting of iron oxide, gold and silica nanoparticles.
